调强放疗时代原发灶剂量不足鼻咽癌的预后
该回顾性研究分析2004至2013年19例接受<66 Gy放疗的鼻咽癌成人患者,按原发灶剂量<54 Gy(A组10例)与≥54 Gy(B组9例)分组。B组5年总生存率88.9%优于A组50.0%(P=.03),接受≥54 Gy但<66 Gy联合诱导化疗者获得良好局部控制与长期生存。
要点
- 原发灶放疗剂量≥54 Gy但<66 Gy联合诱导化疗者预后较好。
- B组5年总生存率88.9%,A组为50.0%,差异有统计学意义(P=.03)。
- B组5年局部区域无复发生存率、无进展生存率、无远处转移生存率均为88.9%以上。
核心结论
- 接受≥54 Gy但<66 Gy放疗联合诱导化疗的鼻咽癌患者获得良好局部控制与长期生存。
研究设计与样本
- 回顾性分析2004至2013年19例组织学确诊的鼻咽癌成人患者,均接受<66 Gy放疗。
- 原发灶剂量<54 Gy者为A组(10例),≥54 Gy者为B组(9例)。
主要发现
- 13例患者接受2或3周期诱导化疗。
- A组5年总生存率为50.0%。
- B组5年总生存率、局部区域无复发生存率、无进展生存率、无远处转移生存率分别为88.9%、100.0%、88.9%、88.9%。
- B组总生存优于A组(88.9% vs 50.0%,P=.03)。
关键数值与推荐
- 原发灶放疗剂量<54 Gy为A组,≥54 Gy为B组,均<66 Gy。
- B组5年总生存率88.9%,A组50.0%,P=.03。
临床怎么用
- 对于接受调强放疗的鼻咽癌成人患者,原发灶剂量≥54 Gy但<66 Gy联合诱导化疗可能获得良好预后。
局限性
- 回顾性研究,样本量小(共19例),分组例数少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It was reported that reduced radiotherapy is feasible for children with nasopharyngeal carcinoma (NPC) and papilloma virus-positive oropharyngeal cancer. Therefore, we performed this study to explore the prognosis of reduced-dose radiation in adult with NPC. METHODS: Between 2004 and 2013, we retrospectively analyzed 19 patients histologically diagnosed with NPC, who received <66 Gy radiation therapy. Ten patients receiving <54 Gy to the primary site were group A. Nine patients receiving ≥54 Gy were group B. RESULTS: Thirteen patients received induction chemotherapy (IC) for two or three cycles. In group A, the 5-year overall survival (OS) was 50.0%. For group B, the 5-year OS, locoregional relapse-free survival, progression-free survival, and distant metastasis-free survival were 88.9%, 100.0%, 88.9%, and 88.9%. Group B had a better prognosis than group A on OS (88.9% vs 50.0%, P = .03). CONCLUSION: Patients receiving ≥54 Gy but <66 Gy with IC achieved good local control and long-term survival.
引用
- Lu T, Xie X, Guo Q, et al. Prognosis of nasopharyngeal carcinoma with insufficient radical dose to the primary site in the intensity-modulated radiotherapy era. Head Neck. 2019. PMID: 31313419. doi:10.1002/hed.25865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。